Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | MMP7 | P09237 | 2/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | F13A1 | P00488 | 2/20 | 0.44 |
| ▸ | TGM2 | P21980 | 2/20 | 0.44 |
| ▸ | TGM1 | P22735 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452029 | 0.94 | GRIN2B (0.53) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL17063265 | 0.92 | GRIN2B (0.57) | MMP1MMP3MMP7MMP9GRIN2B | |
| SCHEMBL19475555 | 0.92 | GRIN2B (0.57) | MMP1MMP3MMP7MMP9GRIN2B | |
| SCHEMBL31488027 | 0.90 | LMNA (0.48) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL4828216 | 0.88 | GRIN2B (0.61) | MMP1MMP3MMP7MMP9GRIN2B | |
| SCHEMBL4274599 | 0.86 | SMN1; SMN2 (0.50) | BCL9CTNNB1MMP1MMP3MMP7 | |
| SCHEMBL3444835 | 0.86 | SMN1; SMN2 (0.50) | BCL9CTNNB1MMP1MMP3MMP7 | |
| SCHEMBL5357194 | 0.84 | SMN1; SMN2 (0.48) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL14438448 | 0.84 | SMN1; SMN2 (0.48) | MMP1MMP3MMP7MMP9MMP13 | |
| SCHEMBL844498 | 0.84 | SMN1; SMN2 (0.48) | MMP1MMP3MMP7MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259800-B2 | Method of fluorination using iodonium ylides | THE GENERAL HOSPITAL CORPORATION (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170121300-A1 | METHOD OF FLUORINATION USING IODONIUM YLIDES | THE GENERAL HOSPITAL CORPORATION | 2017-05-04 | — | — | US | disclosed |
| US-5741792-A | ANTICOAGULANTS OF SULFONAMIDO HETEROCYCLIC THROMBIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| US-5741799-A | ANTICOAGULANTS OF SULFONAMIDO HETEROCYCLIC THROMBIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-21 | — | — | US | disclosed |
| US-5583146-A | Heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0623595-A1 | Guanidinyl- or amidinyl-substituted heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121300-A1 | METHOD OF FLUORINATION USING IODONIUM YLIDES | FLI1, ABL1, PFAS | BCL9 1863/4885CTNNB1 4480/4885MMP1 3081/4885 |
| US-10259800-B2 | Method of fluorination using iodonium ylides | FLI1, ABL1, PFAS | BCL9 1863/4885CTNNB1 4480/4885MMP1 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.